Genocea Biosciences Inc (GNCAQ)

[NY1972]

we also investigated the contribution of T cell-expressed PD-L1 to checkpoint blockade activity.
We found that treating patient T cells alone with anti-PD-L1
triggered significant anti-CLL T cell killing; albeit at a reduced level
compared with the cotreatment of tumor cells (Figure 3D). These
data challenge a prevalent view that tumor cells are the primary
source of PD-L1 during immunosuppressive signaling

https://ashpublications.org/blood/article/137/2/216/464124/Triggering-interferon-signaling-in-T-cells-with